The Novel 5-HT1A Receptor Agonist, NLX-112 Reduces L-DOPA-induced Abnormal Involuntary Movements in Rat: a Chronic Administration Study with Microdialysis Measurements.

Although l-DOPA alleviates the motor symptoms of Parkinson's disease (PD), it elicits troublesome l-DOPA-induced dyskinesia (LID) in a majority of PD patients after prolonged treatment. This is likely due to conversion of l-DOPA to dopamine as a ‘false neurotransmitter’ from serotoninergic neurons. The highly selective and efficacious 5-HT1A receptor agonist, NLX-112 (befiradol or F13640) shows potent activity in a rat model of LID (suppression of Abnormal Involuntary Movements, AIMs) but its anti-AIMs effects have not previously been investigated following repeated administration.